Views & Analysis UK leaders: Takeda’s Jon Neal In the first of a new series where we talk to GMs of UK pharma divisions, managing director for Takeda UK & Ireland, Jon Neal, tells us about the Shire acquisition, rare diseases, a
Views & Analysis Future prospects for an Innovative Medicines Fund for Englan... On the 12 December 2019, the UK general public voted for a further five years of Conservative government.
Views & Analysis An alternative set of metrics for the UK’s pricing and acces... Leela Barham takes a look at alternative ways pharma and the UK government could measure progress for the VPAS.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.